Cabozantinib (Type II), another tyrosine inhibitor targeting c-Met, VEGFR (vascular endothelial growth factor receptor), Mer, and Kit, has been approved for multiple indications: metastatic medullary thyroid cancer, as a second-line treatment of advanced renal cell carcinoma post-antiangiogenic therapy, and as a first-line therapy for advanced renal cell carcinoma [23,24]. The gene discussed is MERTK; the disease is hereditary clear cell renal cell carcinoma.